Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price raised by equities researchers at The Goldman Sachs Group from $31.00 to $35.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 15.17% from the company’s current price.

TEVA has been the topic of several other research reports. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target on the stock. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 13th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. UBS Group raised their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, Bank of America upped their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $31.63.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $30.39 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The stock’s fifty day moving average is $24.44 and its two-hundred day moving average is $20.06. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $30.56. The company has a market capitalization of $34.86 billion, a PE ratio of 50.65, a price-to-earnings-growth ratio of 1.81 and a beta of 0.67.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer owned 5,650 shares in the company, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Sabag sold 216,892 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 622,060 shares of company stock valued at $17,076,965. 0.49% of the stock is owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently modified their holdings of the company. Phoenix Financial Ltd. lifted its position in Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares during the last quarter. Ion Asset Management Ltd. increased its position in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock worth $599,945,000 after purchasing an additional 2,383,500 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after purchasing an additional 427,000 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after purchasing an additional 4,306,363 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 13.6% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock worth $658,161,000 after purchasing an additional 3,896,790 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Goldman Sachs raised its price target on TEVA to $35 and reiterated a “buy” rating, signaling Wall Street conviction in upside versus the current level. Goldman Sachs price target raise
• Positive Sentiment: Additional analyst support: JPMorgan, BofA and Barclays have recently increased targets/ratings (JPMorgan to $35, BofA to $32, Barclays initiating overweight), which likely helped lift sentiment and buying interest. Analyst notes
• Positive Sentiment: Teva’s U.S. affiliate and Alvotech reached a settlement and license with Regeneron setting a U.S. launch window for AVT06 (a proposed biosimilar to Eylea) in Q4 2026 (or earlier under certain conditions) — this reduces launch uncertainty and creates a clearer commercialization timeline. Alvotech settlement
• Neutral Sentiment: Institutional activity is mixed but notable: several funds increased stakes (e.g., Hudson Bay Capital bought more), supporting the view that institutions are accumulating at current levels. Institutional trading
• Neutral Sentiment: Coverage pieces from Zacks and The Motley Fool highlight TEVA as a value/long-term holding — these narrative articles may attract retail interest but are less likely to move price materially on their own. Zacks coverage
• Negative Sentiment: Insider selling: CAO Amir Weiss sold 12,300 shares and Director Roberto Mignone sold 77,400 shares in mid-December at ~\$30.20–30.24 — sizable disclosed sales that may concern some investors about near-term insider conviction. Insider sales

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.